Cell and Gene Therapy Clinical Trials Market

Cell and Gene Therapy Clinical Trials Market Analysis and Forecast by Fact.MR

The global cell and gene therapy clinical trials market is estimated to be around USD 14.31 billion in 2026 and has been forecast to expand at a CAGR of 15.7% to reach USD 61.52 billion by 2036. Demand is shaped by evolving clinical and commercial requirements, expanding institutional infrastructure, and growing adoption of advanced products and solutions across developed and emerging markets. Growth reflects increasing treatment or service intensity, expanding distribution coverage, and rising per-patient or per-unit spending in key end-use segments. The market benefits from sustained investment in product development, regulatory pathway maturation, and the expansion of specialist capacity that supports broader clinical and consumer adoption globally.

Summary of Cell and Gene Therapy Clinical Trials Market

• Market Snapshot
  • In 2025, the global Cell and Gene Therapy Clinical Trials Market was valued at approximately USD 12.37 billion.
  • The market is estimated to reach USD 14.31 billion in 2026 and is projected to attain USD 61.52 billion by 2036.
  • The cell and gene therapy clinical trials market is likely to expand at a CAGR of 15.7% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 47.21 billion between 2026 and 2036.
  • Gene Therapy Trials accounts for 38.6% of trial type share in 2026.
  • China (16.1%) and Japan (15.3%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Expanding institutional adoption and growing clinical or consumer awareness are broadening the addressable market across both developed and emerging geographies.
  • Rising demand intensity per patient or per unit is increasing consumption of products and services within existing end-use channels.
  • Infrastructure expansion in mid-income markets is creating new access points and unlocking latent demand that was previously unaddressed.
  • Regulatory development and compliance requirements are driving adoption of standardised products and certified solutions across institutional settings.
  • Growing e-commerce and direct-to-institution distribution models are improving product accessibility and supporting broader geographic penetration.
• Product and Segment View
  • Gene Therapy Trials accounts for 38.6% of trial type share in 2026, emerging as the leading segment due to broad adoption and established clinical or operational protocols.
  • Early Phase Trials accounts for 42.1% share in 2026, making it the dominant trial phase driven by sustained demand from primary end-use settings.
  • Key segmentation includes:
  • trial type: Gene Therapy Trials and related categories. trial phase: Early Phase Trials and related categories. therapeutic area: Oncology and related categories.
• Geography and Competitive Outlook
  • China leads growth at 16.1% CAGR, supported by expanding infrastructure, rising demand, and growing institutional adoption.
  • Japan follows at 15.3%, driven by demographic shifts, regulatory development, and increasing market access.
  • India (14.9%) and Germany (13.8%) show steady growth supported by established healthcare or commercial infrastructure.
  • Key companies include IQVIA, ICON Plc, LabCorp, Charles River Laboratories, PAREXEL.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The cell and gene therapy clinical trials market is evolving beyond its traditional demand base. Growth is increasingly shaped by expanding institutional adoption, infrastructure scaling in emerging markets, and the shift toward higher-value products and services. Companies that combine reliable product performance with stronger distribution reach and digital engagement are better positioned to capture the next phase of market expansion.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Expanding addressable market driven by demographic shifts, rising awareness, and infrastructure scaling in mid-income economies.
• Growing adoption of premium and advanced products is increasing per-unit or per-patient spending across key segments.
• Regulatory development and compliance mandates are standardising product requirements and driving institutional procurement.

Key Market Constraints

• Pricing pressure from competitive manufacturing and institutional procurement consolidation constrains margin growth.
• Regulatory complexity across jurisdictions increases compliance costs and limits cross-border supply efficiency.
• Reimbursement or funding gaps limit adoption of advanced products in cost-sensitive healthcare or institutional settings.

Key Opportunity Areas

• Geographic expansion into mid-income markets where infrastructure investment is scaling presents significant volume growth.
• Premium product categories that address unmet needs represent a margin expansion opportunity.
• Digital distribution and integrated service models are creating new revenue pathways.

Segment-wise Analysis of the Cell and Gene Therapy Clinical Trials Market

• Gene Therapy Trials holds 38.6% of the trial type segment in 2026, supported by broad institutional adoption and established protocols.
• Early Phase Trials represents 42.1% of the trial phase segment in 2026, driven by sustained demand from primary end-use settings.
• Ex Vivo Therapy holds 44.7% of the therapy approach segment in 2026, reflecting operational preferences and delivery requirements.

The cell and gene therapy clinical trials market is segmented by trial type, trial phase, therapeutic area, and region. By trial type, Gene Therapy Trials leads at 38.6%. Early Phase Trials accounts for 42.1% of the trial phase segment. Oncology represents 51.4% of therapeutic area demand.

Which trial type Segment Dominates the Cell and Gene Therapy Clinical Trials Market?

Gene Therapy Trials accounts for 38.6% of the trial type segment in 2026. Leadership is supported by established adoption across primary end-use settings, broad regulatory clearance, and cost accessibility that sustains high utilisation volumes.

The segment benefits from mature distribution infrastructure and strong institutional familiarity. Growth at the premium end is supported by advanced formulations and enhanced performance characteristics that address evolving requirements.

Which trial phase Segment Dominates the Cell and Gene Therapy Clinical Trials Market?

Early Phase Trials accounts for 42.1% of the trial phase segment in 2026. Demand is shaped by the core clinical or operational requirements of primary end users, with adoption supported by established protocols and institutional procurement patterns.

Growth in this segment reflects both volume expansion in emerging markets and value growth in mature markets where users are shifting toward higher-performance alternatives.

Which Product Trend is Shaping the Next Phase of Growth in the Cell and Gene Therapy Clinical Trials Market?

The fastest-growing segment within the cell and gene therapy clinical trials market reflects a broader shift in buyer expectations toward higher-value, connected, or advanced solutions. This trend is creating a premium tier that supports higher average selling prices and improved margin profiles for manufacturers and service providers.

As adoption of these advanced solutions expands beyond early adopters into mainstream institutional and consumer settings, the growth contribution of this segment is expected to accelerate through the forecast period, supported by improving infrastructure, regulatory acceptance, and distribution coverage.

Regional Outlook Across Key Markets

• China at 16.1% CAGR, supported by expanding infrastructure, rising demand, and growing institutional adoption.
• Japan at 15.3% CAGR, supported by demographic shifts, regulatory development, and increasing market access.
• India at 14.9% CAGR, supported by established institutional demand and steady adoption across core end-use settings.
• Germany at 13.8% CAGR, supported by established institutional demand and steady adoption across core end-use settings.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Cell and Gene Therapy Clinical Trials Market in China

The China cell and gene therapy clinical trials market is projected to grow at a CAGR of 16.1% through 2036. Demand is supported by expanding infrastructure, rising demand intensity, and growing institutional adoption.

• Infrastructure expansion is creating new demand channels.
• Growing adoption of advanced products is increasing per-unit or per-patient spending.
• Regulatory development is supporting broader market access.

Demand Trends in Cell and Gene Therapy Clinical Trials Market in Japan

The Japan cell and gene therapy clinical trials market is projected to grow at a CAGR of 15.3% through 2036. Demand is supported by demographic shifts, regulatory development, and improving market access.

• Infrastructure expansion is creating new demand channels.
• Growing adoption of advanced products is increasing per-unit or per-patient spending.
• Regulatory development is supporting broader market access.

Growth Assessment for Cell and Gene Therapy Clinical Trials Market in India

The India cell and gene therapy clinical trials market is projected to grow at a CAGR of 14.9% through 2036. Demand is supported by demographic shifts, regulatory development, and improving market access.

• Infrastructure expansion is creating new demand channels.
• Growing adoption of advanced products is increasing per-unit or per-patient spending.
• Regulatory development is supporting broader market access.

Market Growth in Cell and Gene Therapy Clinical Trials Market in Germany

The Germany cell and gene therapy clinical trials market is projected to grow at a CAGR of 13.8% through 2036. Demand is supported by established institutional demand and steady adoption across core end-use channels.

• Established networks support consistent procurement demand.
• Growing adoption of advanced products is increasing per-unit or per-patient spending.
• Mature regulatory frameworks support predictable market conditions.

Opportunity Outlook for Cell and Gene Therapy Clinical Trials Market in UK

The UK cell and gene therapy clinical trials market is projected to grow at a CAGR of 12.6% through 2036. Demand is supported by established institutional demand and steady adoption across core end-use channels.

• Established networks support consistent procurement demand.
• Growing adoption of advanced products is increasing per-unit or per-patient spending.
• Mature regulatory frameworks support predictable market conditions.

Demand Analysis for Cell and Gene Therapy Clinical Trials Market in South Korea

The South Korea cell and gene therapy clinical trials market is projected to grow at a CAGR of 11.7% through 2036. Demand is supported by established institutional demand and steady adoption across core end-use channels.

• Established networks support consistent procurement demand.
• Growing adoption of advanced products is increasing per-unit or per-patient spending.
• Mature regulatory frameworks support predictable market conditions.

Competitive Benchmarking and Company Positioning

Cell and Gene Therapy Clinical Trials Market Analysis By Company

• IQVIA, ICON Plc, LabCorp hold established positions through broad portfolios, regulatory compliance, and institutional distribution strength.
• Charles River Laboratories, PAREXEL, Syneos Health compete across specific segments, price tiers, and regional channels.
• Competition is shaped by clinical evidence, distribution reach, portfolio breadth, and institutional procurement relationships.

The competitive landscape is moderately fragmented, with a mix of established and specialist companies. IQVIA, ICON Plc, LabCorp maintain leading positions through comprehensive portfolios, strong institutional relationships, and broad geographic coverage.

Below the top tier, Charles River Laboratories, PAREXEL, Syneos Health, Medpace compete through focused strategies, regional strength, and specialised capabilities. Competition is increasingly shaped by regulatory positioning, clinical evidence, and the ability to integrate products into existing workflows.

Strategic priorities across the market include expanding product portfolios, strengthening distribution in high-growth geographies, and building institutional relationships that support recurring demand and customer retention.

Key Companies in the Cell and Gene Therapy Clinical Trials Market

• IQVIA, ICON Plc, LabCorp, Charles River Laboratories are among the leading players, supported by strong brand visibility, broad product portfolios, and growing positions.
• PAREXEL, Syneos Health, Medpace, Thermo Fisher Scientific hold established positions across specific categories, supported by durable products and channel familiarity.

Leading Companies Shaping the Cell and Gene Therapy Clinical Trials Market

• IQVIA
• ICON Plc
• LabCorp
• Charles River Laboratories
• PAREXEL
• Syneos Health
• Medpace
• Thermo Fisher Scientific
• Novotech
• Veristat LLC

Sources and Research References

• IQVIA. Product portfolio and connected platform updates.
• ICON Plc. Product launches and corporate announcements.
• Industry association statistics, regulatory agency publications, trade data, and company product catalogs.
• Primary interviews with manufacturers, distributors, retailers, and institutional end users.
• This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Cell and Gene Therapy Clinical Trials Market?
• How fast is the Cell and Gene Therapy Clinical Trials Market expected to grow between 2026 and 2036?
• Which trial type is likely to lead the market by 2026?
• Which trial phase segment is expected to account for the highest demand by 2026?
• What factors are driving demand globally?
• Which countries are projected to show the fastest growth through 2036?
• Who are the key companies active in the Cell and Gene Therapy Clinical Trials Market?
• How does Fact.MR estimate and validate the market forecast?

Cell and Gene Therapy Clinical Trials Market Definition

The cell and gene therapy clinical trials market covers products, services, and systems used across institutional, professional, and end-user settings for the defined scope of applications. It includes regulated formulations, devices, and service protocols deployed through hospitals, clinics, specialty centres, and other authorised channels.

Cell and Gene Therapy Clinical Trials Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across trial type, trial phase, therapeutic area, and region.
• It includes regional demand analysis across major geographies, based on prevalence, infrastructure, spending patterns, and adoption trends.
• The report includes pricing and cost analysis, technology trends, market drivers and constraints, and competitive landscape assessment.

Cell and Gene Therapy Clinical Trials Market Exclusions

• The scope excludes adjacent categories not directly classified within the defined market boundary.
• It excludes unregulated consumer products, informal alternatives, and research-only applications without commercial distribution.
• Industrial, military, or custom-built systems outside the defined commercial scope are also excluded.

Cell and Gene Therapy Clinical Trials Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• Primary validation includes 25+ interviews across manufacturers, distributors, and end users.